Citation Information: J Clin Invest. 2007;117(9):2351-2361. https://doi.org/10.1172/JCI31791.
Abstract
Since the effectiveness of androgen deprivation for treatment of advanced prostate cancer was first demonstrated, prevention strategies and medical therapies for prostate cancer have been based on understanding the biologic underpinnings of the disease. Prostate cancer treatment is one of the best examples of a systematic therapeutic approach to target not only the cancer cells themselves, but the microenvironment in which they are proliferating. As the population ages and prostate cancer prevalence increases, challenges remain in the diagnosis of clinically relevant prostate cancer as well as the management of the metastatic and androgen-independent metastatic disease states.
Authors
Russel S. Taichman, Robert D. Loberg, Rohit Mehra, Kenneth J. Pienta
Agents and their presumed targets currently in clinical trial for the treatment of prostate cancer
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)